Physician profile
Mark S Fraley
NPI 1134163819
$6,035.65
in general payments reported to CMS, 2019-2025
43 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $1,314 · 2021: $1,355 · 2022: $756 · 2023: $648 · 2024: $375 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,143.85 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $620.10 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $567.22 | 2019-2025 | Breztri, Farxiga, Fasenra |
| Sanofi-Aventis U.S. LLC | $514.40 | 2019-2023 | |
| Abbvie INC. | $326.46 | 2019-2024 | |
| Amgen INC. | $310.27 | 2019-2024 | Repatha, Otezla |
| Lilly USA, LLC | $257.91 | 2019-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $249.46 | 2019-2025 | M-M-R II, Capvaxive |
| Pfizer INC. | $247.54 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $202.34 | 2019-2023 | Spravato |
| Astellas Pharma US INC | $199.10 | 2019-2023 | Veozah |
| Allergan, INC. | $152.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $124.47 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $118.24 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.71 | 2022-2024 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Fraley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.